LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Search

Simulations Plus Inc

Cerrado

SectorSanidad

11.52 1.32

Resumen

Variación precio

24h

Actual

Mínimo

11.24

Máximo

11.92

Métricas clave

By Trading Economics

Ingresos

1.4M

676K

Ventas

961K

18M

P/B

Media del Sector

48.528

108.767

BPA

-0.034

Rentabilidad por dividendo

0.48

Margen de beneficios

3.67

Empleados

212

EBITDA

-3M

2.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+66.23% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.21%

Próximas Ganancias

2 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-138M

230M

Apertura anterior

10.2

Cierre anterior

11.52

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

96 / 351 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 feb 2026, 23:07 UTC

Ganancias

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb 2026, 23:01 UTC

Ganancias

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb 2026, 22:59 UTC

Ganancias

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 feb 2026, 22:42 UTC

Ganancias

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 feb 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 feb 2026, 23:46 UTC

Charlas de Mercado

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 feb 2026, 23:36 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 feb 2026, 23:30 UTC

Charlas de Mercado

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 feb 2026, 23:20 UTC

Charlas de Mercado

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 feb 2026, 23:20 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

24 feb 2026, 23:16 UTC

Ganancias

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 feb 2026, 23:13 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 feb 2026, 23:12 UTC

Ganancias

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 feb 2026, 23:10 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 feb 2026, 23:10 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 feb 2026, 23:08 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 feb 2026, 23:07 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 feb 2026, 22:52 UTC

Ganancias

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb 2026, 22:46 UTC

Ganancias

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Warner Receives New Bid From Paramount -- 3rd Update

24 feb 2026, 22:29 UTC

Ganancias

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 feb 2026, 22:28 UTC

Ganancias

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 feb 2026, 22:27 UTC

Ganancias

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 feb 2026, 22:27 UTC

Ganancias

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 feb 2026, 22:25 UTC

Ganancias

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 feb 2026, 22:24 UTC

Ganancias

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 feb 2026, 22:23 UTC

Ganancias

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 feb 2026, 22:22 UTC

Ganancias

Woolworths Interim Dividend 45 Australian Cents/Share

24 feb 2026, 22:22 UTC

Ganancias

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 feb 2026, 22:21 UTC

Ganancias

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

66.23% repunte

Estimación a 12 Meses

Media 19 USD  66.23%

Máximo 19 USD

Mínimo 19 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

96 / 351 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat